Lexicon Pharmaceuticals (LXRX) Enterprise Value (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Enterprise Value data on file, last reported at -$170.7 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$170.7 million, up 12.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$170.7 million (up 12.41% YoY), and the FY2025 annual result was -$96.2 million, up 59.56% from the prior year.
• Enterprise Value eased to -$170.7 million in Q1 2026 per LXRX's latest filing, from -$96.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$62.0 million in Q2 2022 and troughed at -$355.6 million in Q1 2024.
• A 5-year average of -$179.6 million and a median of -$170.0 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value plunged 314.31% in 2023, then soared 59.56% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$138.4 million in 2022, then retreated by 22.89% to -$170.0 million in 2023, then plunged by 39.95% to -$238.0 million in 2024, then soared by 59.56% to -$96.2 million in 2025, then slumped by 77.34% to -$170.7 million in 2026.
• Business Quant data shows LXRX's Enterprise Value at -$170.7 million in Q1 2026, -$96.2 million in Q4 2025, and -$116.0 million in Q3 2025.